A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Open accessThe DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.
Abstract
Major advances in understanding the pathogenesis of inherited metabolic disease caused by mitochondrial DNA mutations have yet to translate into treatments of proven efficacy. Leber's hereditary optic neuropathy is the most common mitochondrial DNA disorder causing irreversible blindness in young adult life. Anecdotal reports support the use of idebenone in Leber's hereditary optic neuropathy, but this has not been evaluated in a randomized controlled trial. We conducted a 24-week multi-centre double-blind, randomized, placebo-controlled trial in 85 patients with Leber's hereditary optic neuropathy due to m.3460G>A, m.11778G>A, and m.14484T>C or mitochondrial DNA mutations. The active drug was idebenone 900 mg/day. The primary end-point was the best recovery in visual acuity. The main secondary end-point was the change in best visual acuity. Other secondary end-points were changes in visual acuity of the best eye at baseline and changes in visual acuity for both eyes in each patient. Colour-contrast sensitivity and retinal nerve fibre layer thickness were measured in subgroups. Idebenone was safe and well tolerated. The primary end-point did not reach statistical significance in the intention to treat population. However, post hoc interaction analysis showed a different response to idebenone in patients with discordant visual acuities at baseline; in these patients, all secondary end-points were significantly different between the idebenone and placebo groups. This first randomized controlled trial in the mitochondrial disorder, Leber's hereditary optic neuropathy, provides evidence that patients with discordant visual acuities are the most likely to benefit from idebenone treatment, which is safe and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therapy for LHON has been restricted to supportive measures rather than cure.10”
From Immune Response and Intraocular Inflammation in Patients With Leber Hereditary Optic Neuropathy Treated With Intravitreal Injection of Recombinant Adeno-Associated Virus 2 Carrying the ND4 Gene: A Secondary Analysis of a Phase 1/2 Clinical Trial (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Current treatments for LHON remain inadequate.8 Idebenone (Raxone, Santhera GmbH) was granted market authorization by the European Medicines Agency (EMA) for the treatment of LHON under exceptional circumstances, 9,10 but its benefits are limited.”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
(2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,445
Linear mixed models for longitudinal data
(2000) · Springer Series in Statistics · doi:10.1007/b98969 · Cited by 818
Lange, C., Feltgen, N., Junker, B., Schulze-Bonsel, K., & Bach, M. (2009) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-0926-0 · Cited by 626 · cited 1×
“Patients only able to count fingers, detect hand motion or light perception were assigned logMAR values 2.0, 2.3 and 2.6, respectively (Lange et al., 2009).”
BackgroundInfluentialRiordan-Eva, P., Sanders, M. D., Govan, G. G., Sweeney, M. G., Costa, J. D., & Harding, A. E. (1995) · Brain · doi:10.1093/brain/118.2.319 · Cited by 490
The Epidemiology of Leber Hereditary Optic Neuropathy in the North East of England
Man, P. Y. W., Griffiths, P. G., Brown, D. T., Howell, N., Turnbull, D. M., & Chinnery, P. F. (2003) · The American Journal of Human Genetics · doi:10.1086/346066 · Cited by 483 · cited 1×
“Leber’s hereditary optic neuropathy (LHON; MIM 535000) is the most common mitochondrial disorder affecting more than 1:14 000 males (Man et al., 2003).”
BackgroundSelf-citationNewman, N. J., Lott, M. T., & Wallace, D. C. (1991) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)76784-4 · Cited by 403 · cited 3×
“Most remain legally blind, are unable to drive a motor vehicle, and are unable to find employment (Newman et al., 1991; Riordan-Eva et al., 1995; Nikoskelainen et al., 1996).”
BackgroundResultInfluentialThe epidemiology of mitochondrial disorders—past, present and future
Schaefer, A. M., Taylor, R. W., Turnbull, D. M., & Chinnery, P. F. (2004) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2004.09.005 · Cited by 396 · cited 1×
“Inherited disorders of mitochondrial energy metabolism are a major cause of metabolic disease affecting more than 1/5000 of the population (Schaefer et al., 2004).”
BackgroundSelf-citationBARBONI, P., SAVINI, G., VALENTINO, M., MONTAGNA, P., CORTELLI, P., DENEGRI, A., SADUN, F., BIANCHI, S., LONGANESI, L., & ZANINI, M. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2004.06.034 · Cited by 247 · cited 14×
“Leber’s hereditary optic neuropathy (LHON; MIM 535000) is the most common mitochondrial disorder affecting more than 1:14 000 males (Man et al., 2003).”
BackgroundInfluential
Research works printed but not linked: 1
- Harding AE Sweeney MG Govan GG Riordan-Eva P Pedigree analysis in Leber hereditary optic neuropathy families with a pathogenic mtDNA mutation Am J Hum Genet 1995 57 77 86 7611298 PMC1801226
Cited by
Gorman, G. S., Chinnery, P. F., DiMauro, S., Hirano, M., Koga, Y., McFarland, R., Suomalainen, A., Thorburn, D. R., Zeviani, M., & Turnbull, D. M. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.80 · Cited by 1,563
Self-citationDisturbed mitochondrial dynamics and neurodegenerative disorders
Burté, F., Carelli, V., Chinnery, P. F., & Yu-Wai-Man, P. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.228 · Cited by 660
Self-citationMitochondrial Dysfunction and Oxidative Stress in Alzheimer’s Disease
Misrani, A., Tabassum, S., & Yang, L. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.617588 · Cited by 654
“Idebenone can protect vision loss by enhancing mitochondrial ETC, in individuals with discordant visual acuities (Klopstock et al., 2011).”
BackgroundMitochondrial dysfunction in diabetic kidney disease
Forbes, J. M., & Thorburn, D. R. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2018.9 · Cited by 634
Monogenic Mitochondrial Disorders
Koopman, W. J. H., Willems, P. H. G. M., & Smeitink, J. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1012478 · Cited by 522
Mitochondrial Diseases: Hope for the Future
Russell, O. M., Gorman, G. S., Lightowlers, R. N., & Turnbull, D. M. (2020) · Cell · doi:10.1016/j.cell.2020.02.051 · Cited by 459
Chinnery, P. F., & Hudson, G. (2013) · British Medical Bulletin · doi:10.1093/bmb/ldt017 · Cited by 395
Self-citationThe clinical maze of mitochondrial neurology
DiMauro, S., Schon, E. A., Carelli, V., & Hirano, M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.126 · Cited by 353
Mutations causing mitochondrial disease: What is new and what challenges remain?
Lightowlers, R. N., Taylor, R. W., & Turnbull, D. M. (2015) · Science · doi:10.1126/science.aac7516 · Cited by 341
Complex I deficiency: clinical features, biochemistry and molecular genetics
Fassone, E., & Rahman, S. (2012) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2012-101159 · Cited by 320
Parikh, S., Goldstein, A., Karaa, A., Koenig, M. K., Anselm, I., Brunel-Guitton, C., Christodoulou, J., Cohen, B. H., Dimmock, D., Enns, G. M., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.107 · Cited by 297
Self-citationHealthful aging mediated by inhibition of oxidative stress
Vatner, S. F., Zhang, J., Oydanich, M., Berkman, T., Naftalovich, R., & Vatner, D. E. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101194 · Cited by 238
Yu-Wai-Man, P., Newman, N. J., Carelli, V., Moster, M. L., Biousse, V., Sadun, A. A., Klopstock, T., Vignal-Clermont, C., Sergott, R. C., Rudolph, G., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz7423 · Cited by 232
Self-citationGene Therapy for Leber Hereditary Optic Neuropathy
Feuer, W. J., Schiffman, J. C., Davis, J. L., Porciatti, V., Gonzalez, P., Koilkonda, R. D., Yuan, H., Lalwani, A., Lam, B. L., & Guy, J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.10.025 · Cited by 230
Carelli, V., Carbonelli, M., de Coo, I. F., Kawasaki, A., Klopstock, T., Lagrèze, W. A., La Morgia, C., Newman, N. J., Orssaud, C., Pott, J. W. R., et al. (2017) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000570 · Cited by 228
“A number of publications have recently evaluated the therapeutic benefit of idebenone in LHON, including a placebo-controlled randomized clinical trial of 85 patients treated for 24 weeks with a dosage of 900 mg/day (16,19,20) and a large retrospective case series of 44 patients treated with variable doses of idebenon…”
BackgroundSelf-citationMitochondrial diseases: from molecular mechanisms to therapeutic advances
Wen, H., Deng, H., Li, B., Chen, J., Zhu, J., Zhang, X., Yoshida, S., & Zhou, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02044-3 · Cited by 222
Mitochondrial disease in adults: recent advances and future promise
Ng, Y. S., Bindoff, L. A., Gorman, G. S., Klopstock, T., Kornblum, C., Mancuso, M., McFarland, R., Sue, C. M., Suomalainen, A., Taylor, R. W., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00098-3 · Cited by 218
Self-citationInitial experience in the treatment of inherited mitochondrial disease with EPI-743
Enns, G. M., Kinsman, S. L., Perlman, S. L., Spicer, K. M., Abdenur, J. E., Cohen, B. H., Amagata, A., Barnes, A., Kheifets, V., Shrader, W. D., et al. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.10.009 · Cited by 199
Leber hereditary optic neuropathy: current perspectives.
McClelland, C., Meyerson, C., & Van Stavern, G. (2015) · Clinical Ophthalmology · doi:10.2147/opth.s62021 · Cited by 196
“change in visual acuity for both eyes, particularly for patients with discordant visual acuities.(92) The study also found the largest treatment effect for patients with the 11778 or 3460 mutation, while those with the 14484 mutation had a high spontaneous recovery rate in the placebo group, thought to abolish any tre…”
Therapies for mitochondrial diseases and current clinical trials
El-Hattab, A. W., Zarante, A. M., Almannai, M., & Scaglia, F. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2017.09.009 · Cited by 188
“However, post hoc analysis suggested that idebenone can protect from further vision loss particularly in individuals with discordant visual acuities [18].”
BackgroundMitochondrial complex I-linked disease
Rodenburg, R. J. (2016) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2016.02.012 · Cited by 183
“LHON with idebenone, a short-chain ubiquinone in clinical trials [56, 57].”
BackgroundEfficacy and Safety of rAAV2-ND4 Treatment for Leber’s Hereditary Optic Neuropathy
Wan, X., Pei, H., Zhao, M.-J., Yang, S., Hu, W.-K., He, H., Ma, S.-Q., Zhang, G., Dong, X.-Y., Chen, C., et al. (2016) · Scientific Reports · doi:10.1038/srep21587 · Cited by 182
A neurodegenerative perspective on mitochondrial optic neuropathies
Yu-Wai-Man, P., Votruba, M., Burté, F., La Morgia, C., Barboni, P., & Carelli, V. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1625-2 · Cited by 176
“There is supporting evidence that idebenone can improve the visual prognosis, albeit, partially, in a subgroup of patients that are treated relatively early in the acute stage of LHON [33, 79, 80].”
BackgroundSelf-citationPersistence of the treatment effect of idebenone in Leber’s hereditary optic neuropathy
Klopstock, T., Metz, G., Yu-Wai-Man, P., Büchner, B., Gallenmüller, C., Bailie, M., Nwali, N., Griffiths, P. G., von Livonius, B., Reznicek, L., et al. (2013) · Brain · doi:10.1093/brain/aws279 · Cited by 175
“The underlying mechanism for this may be explained by the natural history and pathophysiology of LHON.”
BackgroundMethodResultInfluentialSelf-citationMitochondrial disease: genetics and management
Ng, Y. S., & Turnbull, D. M. (2016) · Journal of Neurology · doi:10.1007/s00415-015-7884-3 · Cited by 174
Sadun, A. A. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.2972 · Cited by 172
Coenzyme Q10 as a therapy for mitochondrial disease
Hargreaves, I. P. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.01.020 · Cited by 169
Newman, N. J., Yu-Wai-Man, P., Carelli, V., Moster, M. L., Biousse, V., Vignal-Clermont, C., Sergott, R. C., Klopstock, T., Sadun, A. A., Barboni, P., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.12.012 · Cited by 168
“, not able to see letters on the chart) at baseline or nadir and became able to read 5 ETDRS letters on-chart at 1 m.(9,10,26,27) A subject responder was defined as having this response in at least 1 eye at week 96.”
BackgroundSelf-citationNew treatments for mitochondrial disease—no time to drop our standards
Pfeffer, G., Horvath, R., Klopstock, T., Mootha, V. K., Suomalainen, A., Koene, S., Hirano, M., Zeviani, M., Bindoff, L. A., Yu-Wai-Man, P., et al. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.129 · Cited by 167
Self-citationEmerging therapies for mitochondrial diseases
Hirano, M., Emmanuele, V., & Quinzii, C. M. (2018) · Essays in Biochemistry · doi:10.1042/ebc20170114 · Cited by 162
Impaired complex I repair causes recessive Leber’s hereditary optic neuropathy
Stenton, S. L., Sheremet, N. L., Catarino, C. B., Andreeva, N. A., Assouline, Z., Barboni, P., Barel, O., Berutti, R., Bychkov, I. O., Caporali, L., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci138267 · Cited by 163
“2 or greater (29), was observed in 42 eyes (67.”
Self-citationDiagnosis and Treatment of Mitochondrial Myopathies
Ahmed, S. T., Craven, L., Russell, O. M., Turnbull, D. M., & Vincent, A. E. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-00674-4 · Cited by 152
Copper homeostasis and cuproptosis in mitochondria
Tian, Z., Jiang, S., Zhou, J., & Zhang, W. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122223 · Cited by 166
Long-term outcomes of gene therapy for the treatment of Leber’s hereditary optic neuropathy
Yang, S., Ma, S.-Q., Wan, X., He, H., Pei, H., Zhao, M.-J., Chen, C., Wang, D.-W., Dong, X.-Y., Yuan, J.-J., et al. (2016) · eBioMedicine · doi:10.1016/j.ebiom.2016.07.002 · Cited by 139
“3 was considered clinically significant (Yu-Wai-Man et al., 2011; Klopstock et al., 2011).”
BackgroundInfluentialThe effects of idebenone on mitochondrial bioenergetics
Giorgio, V., Petronilli, V., Ghelli, A., Carelli, V., Rugolo, M., Lenaz, G., & Bernardi, P. (2012) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.10.012 · Cited by 138
Mitochondrial disease in adults: what's old and what's new?
Chinnery, P. F. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505079 · Cited by 133
“This is based on a randomised, placebocontrolled, double-blind, trial (900 mg/day) which failed its primary endpoint which was defined as the best recovery in visual acuity (Klopstock et al, 2011).”
Self-citationIdebenone: A Review in Leber’s Hereditary Optic Neuropathy
Lyseng-Williamson, K. A. (2016) · Drugs · doi:10.1007/s40265-016-0574-3 · Cited by 126
“68 indicates patients are unable to read any letters on the ETDRS chart); therefore, decreases in logMAR values indicate improvements in VA [39].”
BackgroundMethodResultInfluentialPharmacological advances in mitochondrial therapy
Singh, A., Faccenda, D., & Campanella, M. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103244 · Cited by 137
Mitochondrial Diseases: A Diagnostic Revolution
Schon, K. R., Ratnaike, T. E., van den Ameele, J., Horváth, R., & Chinnery, P. F. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.06.009 · Cited by 140
Self-citationDiagnosis and clinical features of common optic neuropathies
Biousse, V., & Newman, N. J. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30237-x · Cited by 139
Real-World Clinical Experience With Idebenone in the Treatment of Leber Hereditary Optic Neuropathy
Catarino, C. B., von Livonius, B., Priglinger, C., Banik, R., Matloob, S., Tamhankar, M. A., Castillo, L., Friedburg, C., Halfpenny, C. A., Lincoln, J. A., et al. (2020) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001023 · Cited by 116
“Idebenone was well tolerated, with a good safety profile, in line with results from the RHODOS trial (15).”
BackgroundResultSelf-citationRole of Oxidative Stress in Ocular Diseases Associated with Retinal Ganglion Cells Degeneration
Kang, E. Y., Liu, P., Wen, Y., Quinn, P. M. J., Levi, S. R., Wang, N., & Rong-Kung, T. (2021) · Antioxidants · doi:10.3390/antiox10121948 · Cited by 134
Newman, N. J., Carelli, V., Taiel, M., & Yu-Wai-Man, P. (2020) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001045 · Cited by 111
“(27) 18 (placebo arm) Duration of vision loss (mean): 24.”
BackgroundInfluentialSelf-citationNeuroprotection in Glaucoma: Animal Models and Clinical Trials
Almasieh, M., & Levin, L. A. (2017) · Annual Review of Vision Science · doi:10.1146/annurev-vision-102016-061422 · Cited by 111
“Another approach is to look at the effects of a neuroprotective therapy on the visual outcome in LHON, and a prospective study was performed with idebenone (Klopstock et al. 2011).”
BackgroundDiabetic Retinopathy: The Role of Mitochondria in the Neural Retina and Microvascular Disease
Miller, D. J., Cascio, M. A., & Rosca, M. G. (2020) · Antioxidants · doi:10.3390/antiox9100905 · Cited by 122
Disorders of branched chain amino acid metabolism
Manoli, I., & Venditti, C. P. (2016) · Translational Science of Rare Diseases · doi:10.3233/trd-160009 · Cited by 121
“This is a well-recognized shortcoming in treatment studies for mitochondrial disorders of all principles, where only very few well-conducted randomized controlled studies were able to convincingly show benefit of such therapeutic interventions [114–117].”
BackgroundTreatment of Mitochondrial Disorders
Avula, S., Parikh, S., Demarest, S., Kurz, J. E., & Gropman, A. L. (2014) · Current Treatment Options in Neurology · doi:10.1007/s11940-014-0292-7 · Cited by 108
“A multicenter double-blind randomized placebo-controlled trial [7] (Klopstock et al., 2011) was conducted in 85 patients with LHON optic neuropathy due to mitochondrial DNA mutations.”
Heitz, F. D., Erb, M., Anklin, C., Robay, D., Pernet, V., & Gueven, N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045182 · Cited by 106
“Even though the mouse model used in this study might not replicate the condition in LHON patients in all aspects of the disease, these results strongly support the recently published data showing evidence for a therapeutic benefit of idebenone in prospective and retrospective clinical studies in LHON [40,41,42], and i…”
Bouquet, C., Vignal Clermont, C., Galy, A., Fitoussi, S., Blouin, L., Munk, M. R., Valero, S., Meunier, S., Katz, B., Sahel, J. A., et al. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.6902 · Cited by 104
Koilkonda, R. D., Yu, H., Chou, T.-H., Feuer, W. J., Ruggeri, M., Porciatti, V., Tse, D., Hauswirth, W. W., Chiodo, V., Boye, S. L., et al. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.7630 · Cited by 103
Idebenone: When an antioxidant is not an antioxidant
Gueven, N., Ravishankar, P., Eri, R. D., & Rybalka, E. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101812 · Cited by 113
Modulating Mitophagy in Mitochondrial Disease
Dombi, E., Mortiboys, H., & Poulton, J. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170616101741 · Cited by 98
Focusing on mitochondria in the brain: from biology to therapeutics
Song, N., Mei, S., Wang, X.-X., Hu, G., & Lu, M. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00409-w · Cited by 119
“For the mitochondrial diseases caused by pathogenic variants occurring in the nuclear or mitochondrial genome only symptomatic treatment is available by drugs, metabolic supplements and physical therapy [431–433].”
BackgroundNewman, N. J., Yu-Wai-Man, P., Biousse, V., & Carelli, V. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00174-0 · Cited by 97
Self-citationLam, B. L., Feuer, W. J., Schiffman, J. C., Porciatti, V., Vandenbroucke, R., Rosa, P. R., Gregori, G., & Guy, J. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.7971 · Cited by 96
“Acute better 3 1 (33) [1-91] 130 172 22 27 9 11”
Review of clinical trials for mitochondrial disorders: 1997-2012
Kerr, D. S. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0176-7 · Cited by 96
Erb, M., Hoffmann-Enger, B., Deppe, H., Soeberdt, M., Haefeli, R. H., Rummey, C., Feurer, A., & Gueven, N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036153 · Cited by 95
“alopathy, lactic acidosis and stroke-like episodes (MELAS) [16,17] and Leber’s hereditary optic neuropathy (LHON) [18,19].”
BackgroundSelf-citationOsborne, N. N., & del Olmo‐Aguado, S. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.09.002 · Cited by 104
The optic nerve: A “mito-window” on mitochondrial neurodegeneration
Maresca, A., Morgia, C. L., Caporali, L., Valentino, M. L., & Carelli, V. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.08.004 · Cited by 104
Therapeutic Options in Hereditary Optic Neuropathies
Amore, G., Romagnoli, M., Carbonelli, M., Barboni, P., Carelli, V., & Morgia, C. L. (2020) · Drugs · doi:10.1007/s40265-020-01428-3 · Cited by 98
“Klopstock and co-authors recruited 82 LHON patients carrying one of the three common mutations within 5 years from onset of vision loss [11].”
BackgroundResultCoenzyme Q10 Analogues: Benefits and Challenges for Therapeutics
Suarez-Rivero, J. M., Pastor‐Maldonado, C. J., Povea-Cabello, S., Álvarez-Córdoba, M., Villalón-García, I., Munuera-Cabeza, M., Suárez-Carrillo, A., Talaverón-Rey, M., & Sánchez-Alcázar, J. A. (2021) · Antioxidants · doi:10.3390/antiox10020236 · Cited by 108
“Indeed, as reported in a recent clinical trial with a large cohort of patients, Idebenone succeeded in promoting the recovery of visual acuity in most of the patients [47].”
BackgroundNdufs4 knockout mouse models of Leigh syndrome: pathophysiology and intervention
van de Wal, M. A. E., Adjobo-Hermans, M. J. W., Keijer, J., Schirris, T. J. J., Homberg, J. R., Wieckowski, M. R., Grefte, S., van Schothorst, E. M., van Karnebeek, C., Quintana, A., et al. (2021) · Brain · doi:10.1093/brain/awab426 · Cited by 108
“Idebenone is an antioxidant that rescues vision impairment in CIdeficiency-linked Leber’s hereditary optic neuropathy.(143) However, idebenone treatment did not reverse visual impairment in Ndufs4-WB mice.”
Addressing neurodegeneration in glaucoma: Mechanisms, challenges, and treatments
Ghanem, G. O. B., Wareham, L. K., & Calkins, D. J. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101261 · Cited by 112
“However, post hoc analysis showed that patients with discordant visual acuity at baseline reported improvement in all secondary end-points compared to placebo, including change in BCVA from baseline to week 24 (Klopstock et al., 2011).”
Perspectives of drug-based neuroprotection targeting mitochondria
Procaccio, V., Bris, C., de la Barca, J. M. C., Oca, F., Chevrollier, A., Amati‐Bonneau, P., Bonneau, D., & Reynier, P. (2014) · Revue Neurologique · doi:10.1016/j.neurol.2014.03.005 · Cited by 90
Emerging Mitochondrial Therapeutic Targets in Optic Neuropathies
Sanchez, M. I. G. L., Crowston, J. G., Mackey, D. A., & Trounce, I. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.004 · Cited by 90
Zeviani, M., & Carelli, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010210 · Cited by 95
Cwerman-Thibault, H., Augustin, S., Lechauve, C., Ayache, J., Ellouze, S., Sahel, J.-A., & Corral-Debrinski, M. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.3 · Cited by 86
Mitochondrial disorders: Challenges in diagnosis & treatment
Thangaraj, K., Khan, N., Govindaraj, P., & Meena, A. (2015) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.154489 · Cited by 107
Current and Emerging Clinical Treatment in Mitochondrial Disease
Tinker, R. J., Lim, A. Z., Stefanetti, R. J., & McFarland, R. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00510-6 · Cited by 91
Bottani, E., Lamperti, C., Prigione, A., Tiranti, V., Persico, N., & Brunetti, D. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111083 · Cited by 94
“This study demonstrated the safety and well tolerability of idebenone (900 mg/day for 24 weeks) and reported amelioration of the visual outcome in a subgroup of patients [240].”
BackgroundIdebenone treatment in patients with OPA1-mutant dominant optic atrophy
Barboni, P., Valentino, M. L., Morgia, C. L., Carbonelli, M., Savini, G., Negri, A. M. D., Simonelli, F., Sadun, F., Caporali, L., Maresca, A., et al. (2013) · Brain · doi:10.1093/brain/aws280 · Cited by 86
“Idebenone treatment in patients with OPA1-mutant dominant optic atrophy Piero Barboni,1,2 Maria Lucia Valentino,2,3 Chiara La Morgia,2,3 Michele Carbonelli,1 Giacomo Savini,4 Annamaria De Negri,5 Francesca Simonelli,6 Federico Sadun,7 Leonardo Caporali,2,3 Alessandra Maresca,2,3 Rocco Liguori,2,3 Agostino Baruzzi,2,3…”
BackgroundResultLeber Hereditary Optic Neuropathy: Review of Treatment and Management
Hage, R., & Vignal‐Clermont, C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.651639 · Cited by 88
Targeting NRF2 for the Treatment of Friedreich’s Ataxia: A Comparison among Drugs
Petrillo, S., D’Amico, J., Rosa, P. L., Bertini, E., & Piemonte, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205211 · Cited by 86
“Many of those compounds are already adopted in clinical trials, such as DMF that is used for the treatment of relapsing multiple sclerosis (Tecfidera, Biogen-Idec) [18–20], EPI-743 evaluated in mitochondrial diseases [25,27,28], idebenone, in treating Leber hereditary optic neuropathy (LHON) [29,30] and in FRDA [31,32…”
BackgroundDevelopment of pharmacological strategies for mitochondrial disorders
Kanabus, M., Heales, S. J., & Rahman, S. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12456 · Cited by 78
“A study in LHON did not show a significant change in the primary outcome measure (best eye recovery) but there was a suggestion of improvement in a subgroup (Klopstock et al., 2011).”
BackgroundTraschütz, A., Schirinzi, T., Laugwitz, L., Murray, N. H., Bingman, C. A., Reich, S., Kern, J., Heinzmann, A., Vasco, G., Bertini, E., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25751 · Cited by 84
“37 The ef fi cacy of CoQ10 compounds is now even investigated in more common non-ataxia neurodegenerative diseases (eg, mitochondrial Parkinson ’ s disease), 38 thus highlighting the therapeutic potential of these compounds.”
Self-citationEffects of Idebenone on Color Vision in Patients With Leber Hereditary Optic Neuropathy
Rudolph, G., Dimitriadis, K., Büchner, B., Heck, S., Al-Tamami, J., Seidensticker, F., Rummey, C., Leinonen, M., Meier, T., & Klopstock, T. (2013) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0b013e318272c643 · Cited by 77
Self-citationMoving towards clinical trials for mitochondrial diseases
Pitceathly, R. D. S., Keshavan, N., Rahman, J., & Rahman, S. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12281 · Cited by 82
“In clinical trials, idebenone demonstrated mild improvement of neurological phenotype in Friedreich ataxia and was found to mildly improve visual acuity and colour contrast sensitivity in Leber hereditary optic neuropathy (LHON).(49) It is currently approved for treating LHON in Europe but is not FDA approved.”
BackgroundChadderton, N., Palfi, A., Millington-Ward, S., Gobbo, O., Overlack, N., Carrigan, M., O'Reilly, M., Campbell, M., Ehrhardt, C., Wolfrum, U., et al. (2013) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.112 · Cited by 76
Fourcade, S., Ferrer, I., & Pujol, A. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.05.041 · Cited by 76
Natural history of patients with Leber hereditary optic neuropathy—results from the REALITY study
Yu-Wai-Man, P., Newman, N. J., Carelli, V., La Morgia, C., Biousse, V., Bandello, F. M., Clermont, C. V., Campillo, L. C., Leruez, S., Moster, M. L., et al. (2022) · Eye · doi:10.1038/s41433-021-01535-9 · Cited by 74
Self-citationBiousse, V., Newman, N. J., Yu-Wai-Man, P., Carelli, V., Moster, M. L., Vignal-Clermont, C., Klopstock, T., Sadun, A. A., Sergott, R. C., Hage, R., et al. (2021) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001367 · Cited by 78
“LHON (2,4,5), there is still a pressing medical need for further”
BackgroundSelf-citationMitochondrial dysfunction in central nervous system white matter disorders
Morató, L., Bertini, E., Verrigni, D., Ardissone, A., Ruíz, M., Ferrer, I., Uziel, G., & Pujol, A. (2014) · Glia · doi:10.1002/glia.22670 · Cited by 81
“In addition, a recent observational follow-up study proved that the therapeutic effect of the 24-week-treatement (Klopstock et al., 2011) was maintained 30 months after the therapy was terminated (NCT01421381) (Klopstock et al., 2013).”
BackgroundInfluentialOPA1: How much do we know to approach therapy?
Dotto, V. D., Fogazza, M., Lenaers, G., Rugolo, M., Carelli, V., & Zanna, C. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.018 · Cited by 79
Horváth, R. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9434-1 · Cited by 73
“A recent study showed improvement of 900 mg/day Idebenone in some patients with Leber hereditary optic neuropathy (LHON) (Klopstock et al. 2011), without biochemical evidence of a CoQ10 deficiency.”
BackgroundClinical trials in mitochondrial disorders, an update
Almannai, M., El‐Hattab, A. W., Ali, M. N., Soler‐Alfonso, C., & Scaglia, F. (2020) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2020.10.002 · Cited by 76
Pisano, A., Preziuso, C., Iommarini, L., Perli, E., Grazioli, P., Campese, A. F., Maresca, A., Montopoli, M., Masuelli, L., Sadun, A. A., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv396 · Cited by 73
“In fact, although the administration of antioxidants such as idebenone and EPI-743 showed encouraging results in promoting partial recovery of visual function (6,7,8,9), optic atrophy and permanent blindness still remain the usual outcomes of LHON.”
BackgroundYu‐Wai‐Man, P., Soiferman, D., Moore, D. G., Burté, F., & Saada, A. (2017) · Mitochondrion · doi:10.1016/j.mito.2017.01.004 · Cited by 76
Self-citationDavis, R. L., Liang, C., & Sue, C. M. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63233-3.00010-5 · Cited by 82
Leber hereditary optic neuropathy: bridging the translational gap
Jurkute, N., & Yu-Wai-Man, P. (2017) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000410 · Cited by 70
Self-citationShukla, P., Mandalla, A., Elrick, M. J., & Venkatesan, A. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.628811 · Cited by 78
Chun, B. Y., & Rizzo, J. F. (2017) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2017.06.001 · Cited by 67
Effect of age, diet, and tissue type on PCr response to creatine supplementation
Solis, M. Y., Artioli, G. G., Otaduy, M. C. G., Leite, C. D. C., Arruda, W., Veiga, R. R., & Gualano, B. (2017) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00248.2017 · Cited by 66
Levy, S., Weiss, J., & Benes, S. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.193251 · Cited by 70
“Four of five patients demonstrated an improvement in visual function (Klopstock et al., 2011).”
Newman, N. J., Yu-Wai-Man, P., Carelli, V., Biousse, V., Moster, M. L., Vignal-Clermont, C., Sergott, R. C., Klopstock, T., Sadun, A. A., Girmens, J.-F., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.662838 · Cited by 64
“12:662838. doi: 10.3389/fneur.2021.662838 Intravitreal Gene Therapy vs. Natural History in Patients With Leber Hereditary Optic Neuropathy Carrying the m.11778G>A ND4 Mutation: Systematic Review and Indirect Comparison Nancy J. Newman 1*, Patrick Yu-Wai-Man 2,3,4,5, Valerio Carelli 6,7, Valerie Biousse 1, Mark L. Most…”
BackgroundInfluentialSelf-citationTargeting mitochondrial dysfunction as in aging and glaucoma
Osborne, N. N., Núñez‐Álvarez, C., & del Olmo‐Aguado, S. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.05.010 · Cited by 68
Leber Hereditary Optic Neuropathy: Exemplar of an mtDNA Disease
Wallace, D. C., & Lott, M. T. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_2 · Cited by 67
“The CoQ analogue, idebenone (2.3-dimethoxy-5-methyl-6- (10-hydroxydecyl)-1,4-benzoquinone), has been reported to be beneficial in both open label studies (Mashima et al. 2000; Carelli et al. 2011) and a double blind trial (Klopstock et al. 2011).”
BackgroundInfluentialMedical Management of Hereditary Optic Neuropathies
Morgia, C. L., Carbonelli, M., Barboni, P., Sadun, A. A., & Carelli, V. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00141 · Cited by 65
“THERAPEUTIC OPTIONS Therapeutic options for hereditary optic neuropathies are still limited (64) and up to now only one randomized double-blind placebo-controlled study with idebenone in LHON has been concluded (65).”
BackgroundTarnopolsky, M. A. (2016) · Continuum · doi:10.1212/con.0000000000000403 · Cited by 61
Treatment of hereditary optic neuropathies
Newman, N. J. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.167 · Cited by 61
“14484T>C) and with disease duration of up to five years.(61) The active arm received idebenone (900 mg/day) and no adverse drug reactions occurred over a treatment period of 24 weeks.”
BackgroundOPA1-related disorders: Diversity of clinical expression, modes of inheritance and pathophysiology
de la Barca, J. M. C., Mirebeau‐Prunier, D., Amati‐Bonneau, P., Ferré, M., Sarzi, E., Bris, C., Leruez, S., Chevrollier, A., Desquiret‐Dumas, V., Guéguen, N., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.015 · Cited by 64
“…involved in electron transfer in the mitochondrial respiratory chain, has been tested in this study, after showing some beneficial effects in the treatment of Leber's hereditary optic neuropathy, an inherited optic neuropathy related tomtDNAmutations (Carelli et al., 2011; Klopstock et al., 2011).”
Metadata
- Authors
- Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., Kernt, M., Petraki, D., Rummey, C., Leinonen, M., Metz, G., Griffiths, P. G., Meier, T., & Chinnery, P. F.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- 2 Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne Foundation Hospital, NE1 4LP, NHS Trust, UK
- Centre Hospitalier de l’Université de Montréal (CA)
- Royal Victoria Infirmary (GB)
- Santhera Pharmaceuticals (Switzerland) (CH)
- 8 4Pharma, Stockholm, 16440 Kista, Sweden
- Corresponding author
- Chinnery, Patrick F.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-07-23
- Volume
- 134
- Issue
- 9
- Pages
- 2677-2686
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC3170530
- OpenAlex
- W2124154990
- Cited by
- 578
- References
- 32
- Citations by year
- 2026: 25 · 2025: 35 · 2024: 41 · 2023: 36 · 2022: 44 · 2021: 42 · 2020: 69 · 2019: 39 · 2018: 31 · 2017: 28 · 2016: 61 · 2015: 28 · 2014: 28 · 2013: 29 · 2012: 29
- FWCI
- 16.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Wellcome Trust (01GM0862)
- National Institute for Health and Care Research (NF-SI-0509-10011)
- Parkinson's UK
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung (01GM0862)
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- idebenone, Leber's hereditary optic neuropathy, mitochondrial DNA mutations, mitochondrial disease, visual acuity, retinal nerve fiber layer thickness, treatment response heterogeneity, drug safety and tolerability
- MeSH terms
- Adolescent, Adult, Aged, Antioxidants, DNA, Mitochondrial, Double-Blind Method, Female, Humans, Male, Middle Aged, Mutation, Placebos, Prospective Studies, Retina, Ubiquinone, Visual Acuity, Contrast Sensitivity, Optic Atrophy, Hereditary, Leber, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.